Akv murine leukemia virus enhances bone tumorigenesis in hMT-c-fos-LTR transgenic mice.
hMt-c-fos-LTR transgenic mice (U. Rüther, D. Komitowski, F. R. Schubert, and E. F. Wagner. Oncogene 4, 861-865, 1989) developed bone sarcomas in 20% (3/15) of females at 448 +/- 25 days and in 8% (1/12) of males at 523 days. After infection of newborns with Akv, an infectious retrovirus derived from the ecotropic provirus of the AKR mouse, 69% (20/28) of female animals and 83% (24/29) of males developed malignant fibrous-osseous tumors. The tumors in infected transgenics developed with higher frequency and a 200-days shorter mean tumor latency period. The hMt-c-fos-LTR transgene was expressed in all the fibrous-osseous tumors. They also showed newly integrated Akv proviruses, but in most tumors Akv was detected and expressed in only a small number of the tumor cells. Wild-type C3H mice infected with Akv developed benign osteomas with an incidence of 33% and a latency period of 474 days. The data indicate that Akv exerts distinct pathogenic effects on the skeleton. In hMt-c-fos-LTR transgenic mice, predisposed to bone sarcomagenesis, Akv acts synergistically with the fos transgene, resulting in the development of fibrous-osseous tumors.
Schmidt
J
J
GSF-Institut für Molekulare Virologie, Neuherberg, Oberschleissheim, Germany.
Krump-Konvalinkova
V
V
Luz
A
A
Goralczyk
R
R
Snell
G
G
Wendel
S
S
Dorn
S
S
Pedersen
L
L
Strauss
P G
PG
Erfle
V
V
D000406:AKR murine leukemia virus / Q000472:pathogenicity*; D000818:Animals; D001483:Base Sequence; D001859:Bone Neoplasms / Q000235:genetics / Q000821:virology*; D017931:DNA Primers; D005260:Female; D016762:Genes, fos; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D008822:Mice, Transgenic; D008969:Molecular Sequence Data; D012091:Repetitive Sequences, Nucleic Acid; D012513:Sarcoma, Experimental / Q000235:genetics / Q000821:virology*; D014412:Tumor Virus Infections / Q000235:genetics / Q000821:virology*
D017931:DNA Primers